非提取治疗的衰老与正常未治疗的闭塞的比较:40年随访
Karina Maria Salvatore Freitas1, Camila Massaro2, Felicia Miranda2
1Department of Orthodontics, UNINGÁ University Center, Rod PR 314, 6114, PR, 87035-510, Maringá, Brazil. kmsf@uol.com.br.
Scientific reports
|October 27, 2024
概括
没有提取的正牙治疗导致与正常闭塞相比,不同的长期牙弧变化. 复发显著影响四十年来接受治疗的患者的衰老变化.
科学领域:
- 牙科 牙科是指牙科的专业.
- 矯正牙科 矯正牙科是一種矯正牙科.
- 牙门发展 牙门发展
背景情况:
- ортодонтика治疗对牙弧老化的长期影响尚未完全理解.
- 将非提取治疗的患者与未经治疗的正常闭塞进行比较,可以了解成熟变化.
研究的目的:
- 为了比较四十年的老龄化变化在牙弧的病人治疗正义牙科没有提取与未经治疗的正常闭塞对象.
- 调查复发在长期正牙治疗结果中的作用.
主要方法:
- 追溯性研究比较两个组:非提取治疗 (T组) 和未经治疗的正常闭塞 (UT组).
- 在多个时间点 (治疗前,治疗后,长期治疗后) 进行数字化和分析的牙科件.
- 测量参数包括不规则指数,门宽度,超射,超咬,门长度和周边.
主要成果:
- 接受治疗的组显示出初始拥挤和喷射减少,门宽度增加.
- 在四十年的时间里,与未接受治疗的群体相比,接受治疗的群体在拥挤和长度下降方面经历了更大的增加.
- 过度咬伤在治疗组增加,在未治疗组减少,这表明不同的成熟途径.
结论:
- 牙弧的衰老变化在非提取治疗的正义牙科患者和未治疗的正常闭塞个体之间有显著差异.
- 复发似乎是治疗患者观察到的拥挤和长的长期变化的一个因素.
- 没有提取的正牙治疗影响了牙弧的自然老化过程,长达40年的时间.
更多相关视频
10:14Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
Published on: May 26, 2023
3.0K
07:42Quasistatic Mechanical Testing for Computer-Aided Design and Manufacturing Occlusal Veneers Cemented to Milled Dentin Analog Material
Published on: December 20, 2024
317
相关概念视频
01:17Classification of Illness
The meaning of illness is individualized to each person who experiences an alteration in health. In contrast, disease is a medical term indicating a pathological change in the structure and function of the body or mind. It is a condition that has specific symptoms and boundaries.
An illness is a response to a disease in which the person's level of functioning is changed compared with a previous level. The general classification of illness includes acute and chronic.
Acute illness is severe and...
An illness is a response to a disease in which the person's level of functioning is changed compared with a previous level. The general classification of illness includes acute and chronic.
Acute illness is severe and...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...